18.00
0.05 (0.28%)
| Penutupan Terdahulu | 17.95 |
| Buka | 17.85 |
| Jumlah Dagangan | 399,560 |
| Purata Dagangan (3B) | 544,119 |
| Modal Pasaran | 6,568,956,416 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.86 |
| Harga / Jualan (P/S) | 1.33 |
| Harga / Buku (P/B) | 0.950 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2024 |
| Margin Keuntungan | -7.86% |
| Margin Operasi (TTM) | 5.43% |
| EPS Cair (TTM) | -1.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 69.49% |
| Nisbah Semasa (MRQ) | 1.57 |
| Aliran Tunai Operasi (OCF TTM) | 225.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 137.12 M |
| Pulangan Atas Aset (ROA TTM) | 0.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Bercampur | |
| Stok | Bausch + Lomb Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 88.47% |
| % Dimiliki oleh Institusi | 10.91% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Laurion Capital Management Lp | 30 Sep 2024 | 1,033,880 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 26.00 (Wells Fargo, 44.44%) | Beli |
| Median | 23.00 (27.78%) | |
| Rendah | 18.00 (B of A Securities, 0.00%) | Jual |
| Purata | 22.29 (23.83%) | |
| Jumlah | 4 Beli, 2 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 19.46 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 12 Dec 2024 | 18.00 (0.00%) | Jual | 18.62 |
| HC Wainwright & Co. | 12 Dec 2024 | 23.00 (27.78%) | Beli | 18.62 |
| 31 Oct 2024 | 23.00 (27.78%) | Beli | 20.28 | |
| Citigroup | 11 Dec 2024 | 22.00 (22.22%) | Pegang | 18.16 |
| 31 Oct 2024 | 24.00 (33.33%) | Beli | 20.28 | |
| Morgan Stanley | 02 Dec 2024 | 19.00 (5.56%) | Pegang | 19.47 |
| Wells Fargo | 31 Oct 2024 | 26.00 (44.44%) | Beli | 20.28 |
| RBC Capital | 22 Oct 2024 | 23.00 (27.78%) | Beli | 20.35 |
| Evercore ISI Group | 15 Oct 2024 | 25.00 (38.89%) | Beli | 20.74 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2025 | Pengumuman | Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge |
| 02 Jan 2025 | Pengumuman | Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
| 12 Dec 2024 | Pengumuman | Bausch + Lomb Responds to Rumors of a Potential Sale |
| 11 Dec 2024 | Pengumuman | Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities |
| 14 Nov 2024 | Pengumuman | Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs |
| 30 Oct 2024 | Pengumuman | Bausch + Lomb Announces Third-Quarter 2024 Results |
| 14 Oct 2024 | Pengumuman | Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens |
| 09 Oct 2024 | Pengumuman | Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |